Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate

Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate

ABSTRACT: Objectives: At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pa...

Full description

Bibliographic Details
Main Authors: Mathieu Gendrot, Isabelle Duflot, Manon Boxberger, Océane Delandre, Priscilla Jardot, Marion Le Bideau, Julien Andreani, Isabelle Fonta, Joel Mosnier, Clara Rolland, Sébastien Hutter, Bernard La Scola, Bruno Pradines
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:International Journal of Infectious Diseases
Subjects:
SARS-CoV-2
COVID-19
Antiviral
Antimalarial drug
in vitro
malaria
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220306615

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220306615

Similar Items